Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination.

OBJECTIVES: We examined patient-reported outcomes (PROs) in The Study of Etanercept And Methotrexate in Patients with Psoriatic Arthritis (PsA); a 48-week, phase 3, randomised controlled trial that compared outcomes with methotrexate (MTX) monotherapy, etanercept monotherapy, and MTX+ etanercept in patients with PsA. METHODS: Efficacy endpoints included: mean changes from baseline and proportion of patients who reported improvements≥minimal clinically important difference (MCID) at week 24 in treatment groups for Health Assessment Questionnaire-Disability Index, Patient Global Assessment (PtGA), Patient Global Assessment of Joint Pain (PtGAJP) and Medical Outcomes Study Short Form-36 Questionnaire (SF-36) Physical Component Summary (PCS), and Mental Component Summary, and eight domain scores. PROs were analysed as reported (observed), without multiplicity adjustment; therefore, p values are descriptive. RESULTS: At week 24, patients receiving etanercept monotherapy or MTX+ etanercept combination reported greater improvements (p≤0.05) in PtGA, PtGAJP and SF-36 PCS scores compared with those receiving MTX monotherapy. Compared with MTX monotherapy, higher proportions of patients receiving etanercept monotherapy and combination therapy reported improvements≥MCID in PtGA (etanercept vs MTX, p=0.005) and PtGAJP (MTX +etanercept vs MTX, p=0.038). Across PROs, proportions of patients reporting scores≥age and gender-matched normative values at week 24 ranged from 20.8% to 51.0% with MTX monotherapy, 30.9% to 48.8% with etanercept monotherapy, and 30.6% to 52.3% with MTX+ etanercept combination. CONCLUSIONS: Patients receiving etanercept monotherapy or MTX+ etanercept reported greater improvements from baseline in several PROs compared with those receiving MTX monotherapy. PROs should be incorporated in discussions between patients and clinicians regarding their treatment choices as they can help determine which treatments are more beneficial in patients with PsA

Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome

Rationale: Bronchoalveolar lavage fluid (BAL) from human lung allografts demonstrates the presence of a multipotentmesenchymal stromal cell population. However, the clinical relevance of this novel cellular component of BAL and its association with bronchiolitis obliterans syndrome (BOS), a disease marked by progressive airflow limitation secondary to fibrotic obliteration of the small airways, remains to be determined. Objectives: In this study we investigate the association of number of mesenchymal stromal cells in BAL with development of BOS in human lung transplant recipients. Methods:Mesenchymal colony-forming units (CFUs)were quantitated in a cohort of 405 BAL samples obtained from 162 lung transplant recipients. Poisson generalized estimating equations were used to determine the predictors of BAL mesenchymal CFU count. Measurements and Main Results: Higher CFU counts were noted early post-transplantation; time from transplant to BAL of greater than 3 months predicted 0.4-fold lower CFU counts (P = 0.0001). BOS diagnosis less than or equal to 365 days before BAL was associated with a 2.11-fold higher CFU count (P = 0.02). There were 2.62- and 2.70-fold higher CFU counts noted in the presence of histologic diagnosis of bronchiolitis obliterans (P = 0.05) and organizing pneumonia (0.0003), respectively. In BAL samples obtained from BOS-free patients greater than 6 months post-transplantation (n = 173), higher mesenchymal CFU counts (>=10) significantly predicted BOS onset in both univariate (hazard ratio, 5.61; 95%CI, 3.03–10.38; P < 0.0001) andmultivariate (hazard ratio, 5.02; 95%CI, 2.40–10.51; P < 0.0001) Cox regression analysis. Conclusions: Measurement of mesenchymal CFUs in the BAL provides predictive information regarding future BOS onset.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91951/1/2011 AJRCCM Mesenchymal stromal cells in bronchoalveolar lavage as predictors of bronchiolitis obliterans syndrome.pd

Gender influences health-related Quality of Life in IPF

Disclosure statements Dr. Han has received research support from the NIH. Dr. Bartholmai has received research support from the NIH and GlaxoSmithKline. Dr. Murray has received research support from the NIH. Dr. Giardino has received research support from the VAHS. Dr. Flaherty has received research support from Intermune and the NIH, consulting honorarium from GlaxoSmithKline and is a member of advisory boards for Boehringer Ingelheim and Gilead. Dr. Thompson has received research support from the NIH. Dr. Frederick has received research support from the NIH. Ms. Li has received research support from the NIH. Dr. Schwarz has received research support from the NIH. Dr. Limper received consulting fees and a research grant from Novartis and has received research support from the NIH. Dr. Martinez is a member of a steering committee for Actelion, Gilead, Centocor, and Genzyme and has received research support from Actelion and the NIH.Background HRQL in IPF patients is impaired. Data from other respiratory diseases led us to hypothesize that significant gender differences in HRQL in IPF also exist. Methods Data were drawn from the NIH-sponsored Lung Tissue Research Consortium (LTRC). Demographic and pulmonary physiology data along with MMRC, SF-12, and SGRQ scores from women vs. men were compared with two-sample t-tests. Multivariate linear regression was used to examine the association between SF-12 component scores and gender while adjusting for other relevant variables. Results The study sample consisted of 147 men and 74 women. Among several baseline variables, only DLCO% predicted differed between women and men, (43.7 vs. 38.0, p = 0.03). In general, men exhibited lower (better) MMRC scores (1.7 vs. 2.4, p = 0.02), particularly those with milder disease as measured by DLCO% predicted. In an adjusted analysis, SF-12 PCS scores in men were lower (worse) than women (p = 0.01), an effect that was more pronounced in men with greater dyspnea scores. In a similar analysis, SF-12 MCS scores in women were lower than men (worse) (48.3 vs. 54.4, p = 0.0004), an effect that was more pronounced in women with greater dyspnea scores. Conclusions Significant gender differences in HRQL exist in IPF. As compared to women, men reported less severe dyspnea, had worse SF-12 PCS scores, but better SF-12 MCS scores. Dyspnea appears to have a greater impact on the physical HRQL of men and the emotional HRQL of women. An improved understanding of the mechanism behind these differences is needed to better target interventions.This work is supported by the Lung Tissue Research Consortium (N01 HR46158 (Bartholmai), N01 HR46160 (Schwarz), N01 HR46161 (Limper), N01 HR46162 (Han, Martinez), N01 HR46164 (Li, Frederick, Thompson), KL2 RR024987 (Han), K24 HL04212 (Martinez).Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91956/1/2010 Respiratory Medicine - Gender Influences health-related Quality of Life in IPF.pd

The prognostic value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis

Rationale: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive dyspnea, impaired gas exchange, and ultimate mortality. Objectives: To test the hypothesis that maximal oxygen uptake during cardiopulmonary exercise testing at baseline and with short-term longitudinal measures would predict mortality in patients with idiopathic pulmonary fibrosis. Methods: Data from 117 patients with IPF and longitudinal cardiopulmonary exercise tests were examined retrospectively. Survival was calculated from the date of the first cardiopulmonary exercise test. Measurements and Main Results: Patients with baseline maximal oxygen uptake less than 8.3 ml/kg/min had an increased risk of death (n=8; hazard ratio, 3.24; 95% confidence interval, 1.10–9.56; P = 0.03) after adjusting for age, gender, smoking status, baseline forced vital capacity, and baseline diffusion capacity for carbon monoxide. We were unable to define a unit change in maximal oxygen uptake that predicted survival in our cohort. Conclusions: We conclude that a threshold maximal oxygen uptake of 8.3 ml/kg/min during cardiopulmonary exercise testing at baseline adds prognostic information for patients with IPF.Supported by National Institute of Health NHLBI grant P50HL-56402, NHLBI, 2 K24 HL04212, 1 K23 HL68713, and 1K23 HL077719. C.D.F. was supported by the Alberta Heritage Foundation for Medical Research.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91965/1/2009 AJRCCM The prognostic value of Cardiopulmonary Exercise Testing in Idiopathic Pulmonary Fibrosis.pd

Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease

Background The value of quantitative CT (QCT) to identify chronic obstructive pulmonary disease (COPD) phenotypes is increasingly appreciated. The authors hypothesised that QCT-defined emphysema and airway abnormalities relate to St George’s Respiratory Questionnaire (SGRQ) and Body-Mass Index, Airflow Obstruction, Dyspnea and Exercise Capacity Index (BODE). Methods 1200 COPDGene subjects meeting Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria for COPD with QCT analysis were included. Total lung emphysema was measured using the density mask technique with a 950 Hounsfield unit threshold. An automated programme measured mean wall thickness (WT), wall area percentage (WA%) and 10 mm lumenal perimeter (pi10) in six segmental bronchi. Separate multivariate analyses examined the relative influence of airway measures and emphysema on SGRQ and BODE. Results In separate models predicting SGRQ score, a 1 unit SD increase in each airway measure predicted higher SGRQ scores (for WT, 1.90 points higher, p=0.002; for WA%, 1.52 points higher, p=0.02; for pi10, 2.83 points higher p<0.001). The comparable increase in SGRQ for a 1 unit SD increase in emphysema percentage in these models was relatively weaker, significant only in the pi10 model (for emphysema percentage, 1.45 points higher, p=0.01). In separate models predicting BODE, a 1 unit SD increase in each airway measure predicted higher BODE scores (for WT, 1.07-fold increase, p<0.001; for WA%, 1.20-fold increase, p<0.001; for pi10, 1.16-fold increase, p<0.001). In these models, emphysema more strongly influenced BODE (range 1.24-1.26-fold increase, p<0.001). Conclusion Emphysema and airway disease both relate to clinically important parameters. The relative influence of airway disease is greater for SGRQ; the relative influence of emphysema is greater for BODE.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91946/1/2012 Thorax Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease.pd

Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis

Rationale: Idiopathic pulmonary fibrosis (IPF) and other idiopathic interstitial pneumonias (IIPs) have similar clinical and radiographic features, but their histopathology, response to therapy, and natural history differ. A surgical lung biopsy is often required to distinguish between these entities. Objectives: We sought to determine if clinical variables could predict a histopathologic diagnosis of IPF in patients without honeycomb change on high-resolution computed tomography (HRCT). Methods: Data from 97 patients with biopsy-proven IPF and 38 patients with other IIPs were examined. Logistic regression models were built to identify the clinical variables that predict histopathologic diagnosis of IPF. Measurements and Main Results: Increasing age and average total HRCT interstitial score on HRCT scan of the chest may predict a biopsy confirmation of IPF. Sex, pulmonary function, presence of desaturation, or distance walked during a 6-minute walk test did not help discriminate pulmonary fibrosis from other IIPs. Conclusions: Clinical data may be used to predict a diagnosis of IPF over other IIPs. Validation of these data with a prospective study is needed.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91953/1/2010 AJRCCM Clinical Predictors of a Diagnosis of Idiopathic Pulmonary Fibrosis.pd

Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis

Objectives: To examine which composite measures are most sensitive to change when measuring psoriatic arthritis (PsA) disease activity, analyses compared the responsiveness of composite measures used in a 48-week randomized, controlled trial of MTX and etanercept in patients with PsA. Methods: The trial randomised 851 patients to receive weekly: MTX (20 mg/week), etanercept (50 mg/week) or MTX plus etanercept. Dichotomous composite measures examined included ACR 20/50/70 responses, minimal disease activity (MDA) and very low disease activity (VLDA). Continuous composite measures examined included Disease Activity Score (28 joints) using CRP (DAS28-CRP), Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI), Disease Activity for Psoriatic Arthritis (DAPSA) and Psoriatic Arthritis Disease Activity Score (PASDAS). Results: At week 24, etanercept-treated groups were significantly more effective than MTX monotherapy to achieve ACR 20 (primary end point) and MDA (key secondary end point). When examining score changes from baseline at week 24 across the five continuous composite measures, PASDAS demonstrated relatively greater changes in the etanercept-treated groups compared with MTX monotherapy and had the largest effect size and standardized response. Joint count changes drove overall score changes at week 24 from baseline in all the continuous composite measures except for PASDAS, which was driven by the Physician and Patient Global Assessments. Conclusion: PASDAS was the most sensitive continuous composite measure examined with results that mirrored the protocol-defined primary and key secondary outcomes. Composite measures with multiple domains, such as PASDAS, may better quantify change in PsA disease burden. Trail registration: https://ClinicalTrials.gov, number NCT02376790

Multiple imputation based on restricted mean model for censored data

Most multiple imputation (MI) methods for censored survival data either ignore patient characteristics when imputing a likely event time, or place quite restrictive modeling assumptions on the survival distributions used for imputation. In this research, we propose a robust MI approach that directly imputes restricted lifetimes over the study period based on a model of the mean restricted life as a linear function of covariates. This method has the advantages of retaining patient characteristics when making imputation choices through the restricted mean parameters and does not make assumptions on the shapes of hazards or survival functions. Simulation results show that our method outperforms its closest competitor for modeling restricted mean lifetimes in terms of bias and efficiency in both independent censoring and dependent censoring scenarios. Survival estimates of restricted lifetime model parameters and marginal survival estimates regain much of the precision lost due to censoring. The proposed method is also much less subject to dependent censoring bias captured by covariates in the restricted mean model. This particular feature is observed in a full statistical analysis conducted in the context of the International Breast Cancer Study Group Ludwig Trial V using the proposed methodology. Copyright © 2011 John Wiley & Sons, Ltd.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/84418/1/4163_ftp.pd

Multiple Imputation Based on Restricted Mean Models for Censored Survival Data

Most multiple imputation (MI) methods for censored survival data either ignore patient characteristics when imputing a likely event time, or place quite restrictive modeling assumptions on the survival distributions used for imputation. In this research, we propose a robust MI approach that directly imputes restricted lifetimes over the study period based on a model of the mean restricted life as a linear function of covariates. This method has the advantages of retaining patient characteristics when making imputation choices through the restricted mean parameters and does not make assumptions on the shapes of hazards or survival functions. Simulation results show that our method outperforms its closest competitor for modeling restricted mean lifetimes in terms of bias and efficiency in both independent censoring and dependent censoring scenarios. Survival estimates of restricted lifetime model parameters and marginal survival estimates regain much of the precision lost due to censoring. The proposed method is also much less subject to dependent censoring bias captured by covariates in the restricted mean model. This particular feature is observed in a full statistical analysis conducted in the context of the International Breast Cancer Study Group Ludwig Trial V using the proposed methodology. Copyright © 2011 John Wiley & Sons, Ltd.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/91894/1/Lyrica Stat in Medicine 2011.pd

Caught in the Tractor Beam of Larger Influences: The Filtration of Innovation in Education Technology Design

While emerging technologies continue to emerge, research into their use in learning contexts often focuses on a subset of educational practices and ways of using technologies. In this study we begin to explore the extent to which educational designs are influenced by larger societal and education-related factors not usually explicitly considered when designing or identifying technology-supported education experiences for research study. We examine patterns within and between factors via a content analysis across ten years and 19 different journals of published peer-reviewed research on technology-supported writing. Our findings have implications for how researchers, designers, and educators approach technology-supported educational design within and beyond the field of writing and literacy